Preview

Pharmacy & Pharmacology

Advanced search
Fullscreen

For citations:


Petrov V.I., Ryazanova A.Yu., Tokareva N.S. Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients. Pharmacy & Pharmacology. 2024;12(3):209-218. https://doi.org/10.19163/2307-9266-2024-12-3-209-218



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2307-9266 (Print)
ISSN 2413-2241 (Online)